Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study

doi:10.5306/wjco.v17.i5.120140

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

(11)

(10)

(0)

(184)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. May 24, 2026; 17(5): 120140
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.120140

Open in New Tab Full Size Figure Download Figure

Figure 1 Disease progression/overall survival in good lung immune prognostic index and poor lung immune prognostic index groups. A: The median progression-free survival time was not reached in the good lung immune prognostic index (LIPI) group and 48.0 months in the poor LIPI group (hazard ratio = 0.3035, 95% confidence interval: 0.1054-0.8741; P < 0.05); B: The median overall survival time was not reached in the Good LIPI group and 49.1 months (range 327-52.6 months) in the poor LIPI group (hazard ratio = 0.2263, 95% confidence interval: 0.0760-0.6733; P < 0.05). LIPI: Lung immune prognostic index.

Citation: Gao WH, Luo H, Zhu QY, Jiang Q, Lian LX. Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study. World J Clin Oncol 2026; 17(5): 120140
URL: https://www.wjgnet.com/2218-4333/full/v17/i5/120140.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i5.120140

Gao WH, Luo H, Zhu QY, Jiang Q, Lian LX. Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study. World J Clin Oncol 2026; 17(5): 120140 [DOI: 10.5306/wjco.v17.i5.120140]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.